The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Patients with Idiopathic Pulmonary Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses
Open accessAbstract
Rationale: Diverse autoantibodies are present in most patients with idiopathic pulmonary fibrosis (IPF). We hypothesized that specific autoantibodies may associate with IPF manifestations. Objectives: To identify clinically relevant, antigen-specific immune responses in patients with IPF. Methods: Autoantibodies were detected by immunoblots and ELISA. Intrapulmonary immune processes were evaluated by immunohistochemistry. Anti–heat shock protein 70 (HSP70) IgG was isolated from plasma by immunoaffinity. Flow cytometry was used for leukocyte functional studies. Measurements and Main Results: HSP70 was identified as a potential IPF autoantigen in discovery assays. Anti-HSP70 IgG autoantibodies were detected by immunoblots in 3% of 60 control subjects versus 25% of a cross-sectional IPF cohort (n = 122) (P = 0.0004), one-half the patients with IPF who died (P = 0.008), and 70% of those with acute exacerbations (P = 0.0005). Anti-HSP70 autoantibodies in patients with IPF were significantly associated with HLA allele biases, greater subsequent FVC reductions (P = 0.0004), and lesser 1-year survival (40 ± 10% vs. 80 ± 5%; hazard ratio = 4.2; 95% confidence interval, 2.0–8.6; P < 0.0001). HSP70 protein, antigen–antibody complexes, and complement were prevalent in IPF lungs. HSP70 protein was an autoantigen for IPF CD4 T cells, inducing lymphocyte proliferation (P = 0.004) and IL-4 production (P = 0.01). IPF anti-HSP70 autoantibodies activated monocytes (P = 0.009) and increased monocyte IL-8 production (P = 0.049). ELISA confirmed the association between anti-HSP70 autoreactivity and IPF outcome. Anti-HSP70 autoantibodies were also found in patients with other interstitial lung diseases but were not associated with their clinical progression. Conclusions: Patients with IPF with anti-HSP70 autoantibodies have more near-term lung function deterioration and mortality. These findings suggest antigen-specific immunoassays could provide useful clinical information in individual patients with IPF and may have implications for understanding IPF progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similar findings were observed with the presence of anti-HSP70 autoantibodies in patients with IPF (166).”
From The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis (2018) · cites this paper as [166]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765 · cited 1×
“Antigen(or autoantigen-) activated T cells can cause severe injuries, both directly and/or by production of mediators that activate and recruit other leukocyte, epithelial, and mesenchymal effectors, and these lymphocytes are implicated as the initiation of many diseaseassociated inflammatory cascades (28, 29, 41, 42).”
BackgroundAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationZuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L., Morris, D., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620
Self-citationAutoimmune disease: why and where it occurs
Marrack, P., Kappler, J., & Kotzin, B. L. (2001) · Nature Medicine · doi:10.1038/90935 · Cited by 609 · cited 4×
“Antigen(or autoantigen-) activated T cells can cause severe injuries, both directly and/or by production of mediators that activate and recruit other leukocyte, epithelial, and mesenchymal effectors, and these lymphocytes are implicated as the initiation of many diseaseassociated inflammatory cascades (28, 29, 41, 42).”
BackgroundInfluentialEvidence‐based guidelines for the use of immunologic tests: Antinuclear antibody testing
Solomon, D. H., Kavanaugh, A. J., Schur, P. H., & American College of Rheumatology Ad Hoc Committee on Immunologic Testing Guidelines (2002) · Arthritis Care & Research · doi:10.1002/art.10561 · Cited by 510
Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis
Richards, T. J., Kaminski, N., Baribaud, F., Flavin, S., Brodmerkel, C., Horowitz, D., Li, K., Choi, J., Vuga, L. J., Lindell, K. O., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0058oc · Cited by 381 · cited 1×
“IL-8 expression is a correlate (and possible mediator) of IPF pathogenesis (36).”
BackgroundSelf-citationThe clinical relevance of autoantibodies in scleroderma.
Ho, K. T., & Reveille, J. D. (2003) · Arthritis Research · doi:10.1186/ar628 · Cited by 337
Franks, A. L., & Slansky, J. E. (2012) · PubMed · Cited by 326
The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
Cancro, M. P., D’Cruz, D. P., & Khamashta, M. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci38010 · Cited by 283
Research works printed but not linked: 1
- Xue, 2011, Decreased survival of idiopathic pulmonary fibrosis patients with heat shock protein 70 autoreactivity [abstract], Am J Respir Crit Care Med, 183, A4275
Cited by
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report
Collard, H. R., Ryerson, C. J., Corte, T. J., Jenkins, G., Kondoh, Y., Lederer, D. J., Lee, J. S., Maher, T. M., Wells, A. U., Antoniou, K. M., et al. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201604-0801ci · Cited by 1,444
Self-citationMartinez, F. J., Collard, H. R., Pardo, A., Raghu, G., Richeldi, L., Selman, M., Swigris, J. J., Taniguchi, H., & Wells, A. U. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.74 · Cited by 1,388
Shared and distinct mechanisms of fibrosis
Distler, J. H. W., Györfi, A.-H., Ramanujam, M., Whitfield, M. L., Königshoff, M., & Lafyatis, R. (2019) · Nature Reviews Rheumatology · doi:10.1038/s41584-019-0322-7 · Cited by 637
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Selman, M., & Pardo, A. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201312-2221pp · Cited by 454
Metadata
- Authors
- Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., Gibson, K. F., Kaminski, N., Banga, G., Oddis, C. V., Pilewski, J. M., Sciurba, F. C., Donahoe, M., Zhang, Y., & Duncan, S. R.
- Affiliations
- University of Pittsburgh (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- Duncan, Steven R.
- ORCID
- Venue
- American Journal of Respiratory and Critical Care Medicine
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-04-01
- Volume
- 187
- Issue
- 7
- Pages
- 768-775
- ISSN
- 1073-449X (ISSN-L)
- 1535-4970
- PMC
- PMC3678112
- OpenAlex
- W2142374046
- Cited by
- 190
- References
- 48
- Citations by year
- 2026: 5 · 2025: 11 · 2024: 6 · 2023: 8 · 2022: 13 · 2021: 13 · 2020: 14 · 2019: 17 · 2018: 22 · 2017: 19 · 2016: 12 · 2015: 16 · 2014: 16 · 2013: 18
- FWCI
- 12.89
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- American Journal of Respiratory and Critical Care Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5p50hl084932-05, UL1TR000005, HL084948)
- National Heart, Lung, and Blood Institute (K08HL083085, HL084948, HL007563, HL084932, P50-HL-084932, P50HL107172, U01HL112711, P50HL084948, HL107172, HL112711, T32HL007563)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Rheumatology › Systemic Sclerosis and Related Diseases
- Health Sciences › Medicine › Rheumatology › IgG4-Related and Inflammatory Diseases
- Keywords
- idiopathic pulmonary fibrosis, HSP70, autoantigens, prognosis, survival, lung function decline, acute exacerbation, CD4+ T cells, monocytes, interleukin-8, IL-4, complement system, interstitial lung disease, autoimmunity
- MeSH terms
- Aged, Antigen-Antibody Complex, Autoantibodies, Enzyme-Linked Immunosorbent Assay, Female, Humans, Immunoglobulin G, Immunohistochemistry, Lung, Male, Prognosis, Interleukin-4, Linear Models, Proportional Hazards Models, Interleukin-8, HSP70 Heat-Shock Proteins, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patients with Idiopathic Pulmonary Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses. https://app.cochat.ai/papers/10.1164/rccm.201203-0506oc
- The paper
- Kahloon, R. A., Xue, J., Bhargava, A., Csizmadia, E., Otterbein, L., Kass, D. J., Bon, J., Soejima, M., Levesque, M. C., Lindell, K. O., Gibson, K. F., Kaminski, N., Banga, G., Oddis, C. V., Pilewski, J. M., Sciurba, F. C., Donahoe, M., Zhang, Y., & Duncan, S. R. (2013). Patients with Idiopathic Pulmonary Fibrosis with Antibodies to Heat Shock Protein 70 Have Poor Prognoses. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.201203-0506oc
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.